The role of previously unmeasured organic acids in the pathogenesis of severe malaria by Herdman, M. Trend et al.
Herdman et al. Critical Care  (2015) 19:317 
DOI 10.1186/s13054-015-1023-5RESEARCH Open AccessThe role of previously unmeasured organic
acids in the pathogenesis of severe malaria
M. Trent Herdman1, Natthida Sriboonvorakul1,2,3, Stije J. Leopold1, Sam Douthwaite1, Sanjib Mohanty4,
M. Mahtab Uddin Hassan5, Richard J. Maude1,6, Hugh WF Kingston1,7, Katherine Plewes1,
Prakaykaew Charunwatthana1,3, Kamolrat Silamut1, Charles J. Woodrow1,6, Kesinee Chotinavich1,3,
Md. Amir Hossain5, M. Abul Faiz8, Saroj Mishra4, Natchanun Leepipatpiboon2, Nicholas J. White1,6,
Nicholas PJ Day1,6, Joel Tarning1,6 and Arjen M. Dondorp1,6*Abstract
Introduction: Severe falciparum malaria is commonly complicated by metabolic acidosis. Together with lactic acid
(LA), other previously unmeasured acids have been implicated in the pathogenesis of falciparum malaria.
Methods: In this prospective study, we characterised organic acids in adults with severe falciparum malaria in India
and Bangladesh. Liquid chromatography-mass spectrometry was used to measure organic acids in plasma and
urine. Patients were followed until recovery or death.
Results: Patients with severe malaria (n=138), uncomplicated malaria (n=102), sepsis (n=32) and febrile encephalopathy
(n=35) were included. Strong ion gap (mean±SD) was elevated in severe malaria (8.2 mEq/L±4.5) and severe
sepsis (8.6 mEq/L±7.7) compared with uncomplicated malaria (6.0 mEq/L±5.1) and encephalopathy (6.6 mEq/L±4.7).
Compared with uncomplicated malaria, severe malaria was characterised by elevated plasma LA, hydroxyphenyllactic
acid (HPLA), α-hydroxybutyric acid and β-hydroxybutyric acid (all P<0.05). In urine, concentrations of methylmalonic,
ethylmalonic and α-ketoglutaric acids were also elevated. Multivariate logistic regression showed that plasma HPLA was a
strong independent predictor of death (odds ratio [OR] 3.5, 95 % confidence interval [CI] 1.6–7.5, P=0.001), comparable to
LA (OR 3.5, 95 % CI 1.5–7.8, P=0.003) (combined area under the receiver operating characteristic curve 0.81).
Conclusions: Newly identified acids, in addition to LA, are elevated in patients with severe malaria and are highly
predictive of fatal outcome. Further characterisation of their sources and metabolic pathways is now needed.Introduction
Severe falciparum malaria remains a leading cause of
mortality in the tropics. The case fatality rate in adult
patients remains between 15 % and 40 % in resource-
constrained hospital settings, and it is 11 % in intensive care
units in resource-rich settings [1–3]. A better understand-
ing of the pathophysiology of severe malaria is necessary to
guide the development of new therapies.
The degree of metabolic acidosis in severe malaria is a
strong prognosticator for a fatal outcome. Acidosis is
associated with hyperlactataemia, and lactic acid (LA)* Correspondence: arjen@tropmedres.ac
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hydrogen ion accumulation [4, 5]. In contrast to bacter-
ial sepsis, shock is not a common manifestation of
severe malaria. Profound hyperlactataemia can occur in
the presence of apparently normal macrovascular circu-
lation [6, 7]. In severe falciparum malaria, sequestration
of parasitised erythrocytes in capillaries and venules im-
pairs oxygen delivery, leading to anaerobic glycolysis and
consequent lactic acidosis with an increased lactate/
pyruvate ratio [4, 8–10]. Further compromise of the
microcirculatory flow occurs as a result of reduced
erythrocyte deformability, rosette formation, agglutination,
of parasitised erythrocytes, severe anaemia and endothelial
dysfunction [4, 11, 12]. Compounding increased lactate
production, clearance of lactate may be reduced owing to
impaired gluconeogenesis and decreased liver blood flowcle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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through loss of the kidney’s normal role in acid–base
homeostasis [14]. Yet, hyperlactataemia and renal dys-
function together still account for only two-thirds of the
variance in standard base deficit (SBD) [4].
Using the modified physicochemical approach of Stewart,
the presence of an unmeasured anion load was detected
in patients with severe malaria [15, 16]. The mean (95 %
confidence interval [CI]) strong ion gap (SIG), represent-
ing unmeasured acids, was 11.1 (10.4–11.8) mEq/L (nor-
mal value 0–2 mEq/L), whilst the mean concentration of
lactate was only 2.9 mmol/L (2.7–3.2). The SIG showed
an independent correlation with mortality [16]. This sug-
gests that, in addition to LA accumulation, other organic
acids play an important role in the pathogenesis of severe
malaria. The prognostic value and pathological import-
ance of such organic acids has also been recognised in
other critical illnesses, including bacterial sepsis [17–19].
Understanding of the pathophysiology of severe malaria
can be enhanced by profiling hitherto unidentified acids
and comparing this profile with the profiles of other dis-
ease states.
Using a recently developed liquid chromatography-
mass spectrometry (LC-MS) assay [20], we quantified a
range of additional acids in the plasma and urine of
adults with severe malaria to assess these acids’ contri-
butions to acid load and their prognostic significance.
Reference groups of uncomplicated falciparum malaria,
bacterial sepsis (as an alternative cause of metabolic
acidosis) and non-malarial encephalopathy (as an alter-
native cause of fever and coma) were also characterised.
Methods
Site selection and participants
This observational study was conducted in Chittagong
Medical College Hospital, Chittagong, Bangladesh, and
Ispat General Hospital, Rourkela, India, from May 2009
to September 2012. Both are areas of low, seasonal mal-
aria transmission. Non-pregnant adults older than 16
years of age were recruited into this prospective study.
There were four clinical diagnostic categories: (1) un-
complicated falciparum malaria, (2) severe falciparum
malaria, (3) sepsis (in the absence of malaria) and (4)
non-malarial febrile encephalopathy. Malaria was defined
by the presence of asexual Plasmodium falciparum para-
sites visualised on a peripheral blood film, and severe mal-
aria was distinguished from uncomplicated malaria by the
presence of one or more markers of severity according to
modified World Health Organisation (WHO) criteria as
defined by Tran et al. [21]. Sepsis was defined by a blood
film negative for malaria of all species, clinical suspicion
of bacterial infection (based on history, examination and,
when available, complete blood count and other investiga-
tions), SBD ≥3 mEq/L and two or more of the followingfour criteria: (1) heart rate >90 beats per minute, (2)
respiratory rate >20 breaths per minute, (3) systolic blood
pressure <90 mmHg and/or (4) Glasgow Coma Scale
(GCS) score <15. Encephalopathy was defined by a blood
film negative for malaria of all species, documented fever
(>37.5 °C), a GCS score <11 and onset of symptoms
within 14 days of admission without an obvious non-
infective aetiology (such as diabetic ketoacidosis or poi-
soning). Participants meeting the inclusion criteria for
both sepsis and encephalopathy were classified as having
sepsis. Participants with chronic kidney or liver disease
were excluded.
Fully informed consent was obtained from the patient
or a legally acceptable representative. The Chittagong
Medical College Hospital Ethical Review Committee, the
Ispat General Hospital Institutional Ethical Committee
and the Oxford Tropical Research Ethics Committee
approved this study.
Study procedures
A detailed medical history and physical examination
were performed upon enrolment, and each patient was
monitored until discharge from the hospital or death.
Anti-malarial medications and supportive therapies were
administered in accordance with the WHO’s 2006 and
2010 malaria treatment guidelines and local hospital
guidelines, although the availability of renal replacement
therapy and mechanical ventilation was limited. Partici-
pants with sepsis or encephalopathy were treated ac-
cording to hospital guidelines. Fluid management was
carried out according to the attending physician’s discre-
tion and typically entailed crystalloid administration
guided by non-invasive monitoring. Upon patient admis-
sion, venous blood was collected for immediate pro-
cessing in the hospital laboratory. Glucose, sodium,
potassium, chloride, pH and partial pressure of carbon
dioxide (pCO2) were assessed with an iSTAT point-of-
care analyser (Abbott Point of Care, Maidenhead, UK).
Bicarbonate (HCO3
−) and SBD were derived internally
from measurements of pH and pCO2 by using the
iSTAT software. Haemoglobin and parasite count were
determined using samples anti-coagulated with ethylene-
diaminetetraacetic acid (EDTA). Magnesium, calcium,
phosphate, albumin, creatinine and total bilirubin were
measured using freeze-thawed stored serum samples.
L-Lactate was measured in plasma stored at −80 °C
with fluoride/oxalate using the Olympus OSR 6193 sys-
tem reagents for enzymatic quantification (Olympus
Life Science, Southend-on-Sea, UK). Plasma Plasmodium
falciparum histidine-rich protein 2 (PfHRP2) concentra-
tions were assessed from freeze-thawed plasma stored
with EDTA using a commercial sandwich enzyme-linked
immunosorbent assay kit (Cellabs, Brookvale, Australia)
as described previously [9]. Urine for assessment of acids
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Liquid chromatography-mass spectroscopy of plasma and
urine
Heparinised venous blood for LC-MS was centrifuged at
4 °C and 1500×g for 5 minutes, and plasma was stored
at −80 °C or in liquid nitrogen until analysis. Unpro-
cessed urine was stored in the same manner. The novel
analytical techniques employed are described in detail
elsewhere [20]. This technique permits simultaneous
assessment of eight organic acids: LA, malonic acid
(MA), methylmalonic acid (MMA), α-hydroxybutyric
acid (α-HBA), β-hydroxybutyric acid (β-HBA), hydroxy-
phenyllactic acid (HPLA), ethylmalonic acid (EMA), and
α-ketoglutaric acid (α-KGA). Urine concentrations were
corrected for renal function by using the formula
[A]urine-corrected = [A]urine × [Cre]plasma/[Cre]urine, as
described previously for other urine substrates [22].
Calculation of the strong ion gap and unmeasured anions
The apparent strong ion difference (SIDapp) was calculated
as SIDapp = [Na
+] + [K+] + [Ca2+] + [Mg2+] − [Cl−] −
[lactate−], with all concentrations expressed in milliequi-
valents per litre. The effective strong ion difference
(SIDeff ) was calculated by inclusion of the charges con-
tributed by HCO3
−, albumin and inorganic phosphate,
using calculations described previously [16]. SIG was
calculated as SIDapp − SIDeff as a measure of the re-
maining balance of charges contributed by unmeasured
strong ions, including organic acids, and dissociated
weak acids. For consistency with previous reports of the
pathogenesis of acidosis in severe malaria, the SIG was
calculated incorporating L-lactate derived by enzymatic
assay.
Statistical analysis
Statistical analysis was performed using STATA/IC 12.0
software (StataCorp, College Station, TX, USA) and
Prism 6.0b software (GraphPad Software, La Jolla, CA,
USA). Normally distributed continuous variables and log-
transformed variables were compared between groups
using analysis of variance, with post-test pairwise compar-
isons as appropriate, using Tukey’s multiple-comparisons
test. Non-normally distributed data were compared
using the Mann–Whitney U test. Associations between
organic acids, clinical indicators and mortality caused
by severe malaria were formally explored by calculation
of Spearman’s rank correlation coefficient. For potential
predictors of fatal outcome, odds ratios (ORs) and P
values were determined by univariate logistic regres-
sion. Inclusion of explanatory variables in a multivariate
model was hypothesis-driven. Two multivariate logistic re-
gression models were designed, one including the fourdetectable plasma acids and one including the seven de-
tectable urinary acids. Both models were assessed for col-
linearity using the ‘collin’ function in STATA/IC. Stepwise
backward selection with a P-value cutoff of <0.05 was
done to come to a final multivariate logistic regression
model. For the final models, the area under the receiver
operating characteristic curve (AUROCC) was deter-
mined, and goodness-of-fit was measured using the
Hosmer-Lemeshow test and determination of the model’s
P value.
Results
Baseline characteristics of the study population
A total of 138 consecutive patients with severe malaria
and 102 with uncomplicated malaria were recruited to
participate in this study. Non-malarial reference groups
of acutely ill patients included 32 consecutively recruited
participants with sepsis and 35 with febrile encephalop-
athy. At the time of admission, 63 % of patients with
severe malaria were comatose, 46 % had jaundice, 17 %
were severely anaemic, 16 % had acute kidney injury, 2
% were hypoglycaemic and 1 % had haemodynamic
shock. Mortality rates were 28 % among participants
with severe malaria, 50 % for those with sepsis and 43 %
for patients with encephalopathy. The clinical and bio-
chemical characteristics of these participants at the time
of enrolment are shown in Table 1.
Metabolic acidosis and the strong ion gap
The majority of participants with severe malaria had
metabolic acidosis (mean SBD 6 mEq/L) (Table 2), but
only 14 % of patients with severe malaria had a venous
pH <7.35 compared with 47 % of patients with sepsis.
SBD was different between groups (P<0.001), with
higher mean SBD in patients with sepsis than in those
severe malaria and higher SBD in patients with severe
malaria than in patients with uncomplicated malaria or
encephalopathy. SIG differed between study groups
(P=0.002) and was higher in patients with severe malaria,
sepsis or encephalopathy than in patients with uncompli-
cated malaria.
Identification of organic acids in plasma and urine
Of the eight candidate acids sought by LC-MS, four
were present at detectable levels in both plasma and
urine: LA, α-HBA, β-HBA and HPLA. EMA, MMA and
α-KGA were undetectable in plasma but were detectable
in urine. MA was undetectable in both plasma and
urine. Table 3 summarises the observed range of acids
detected in plasma and urine specimens taken from the
study groups at the time of admission. Figures 1 and 2
compare plasma and corrected urine concentrations,
respectively, between study groups.
Table 1 Baseline clinical and biochemical characteristics of participants at the time of enrolment
Characteristics Uncomplicated malaria
N=102
Severe malaria
N=138
Sepsis
N=32
Encephalopathy
N=35
P value*
Male, n (%) 80 (78 %) 97 (70 %) 15 (47 %) 23 (66 %) 0.008
Age, yr, mean (SD, range) 33 (14.8, 16–70) 36 (14.2, 16–75) 37 (14.7, 16–70) 40 (18.4, 18–75) 0.106
Respiratory rate, breaths/min,
mean (SD, range)
26 (6.6, 18–48) 32 (10.2, 15–93) 34 (9.9, 15–58) 30 (9.4, 12–60) <0.001
Heart rate, beats/min, mean
(SD, range)
95 (16.2, 64–149) 110 (22.5, 54–166) 120 (16.9, 92–151) 104 (24.7, 60–170) <0.001
Mean arterial pressure, mmHg,
mean (SD, range)
81 (11.7, 57–115) 83 (15.2, 28–144) 79 (19.3, 20–127) 93 (17.1, 64–125) <0.001
Shock, SBP <80 mmHg, n (%) 0 (0 %) 2 (1.4 %) 6 (19 %) 0 (0 %)
Glasgow Coma Scale score,
geo mean (95 % CI)
15 (15–15) 9 (9–10) 11 (9–13) 7 (6–8) <0.001
GCS score <15, n (%) 15/102 (15 %) 109/138 (79 %) 17/32 (53 %) 35/35 (100 %)
GCS score <11, n (%) 0 (0 %) 87/138 (63 %) 10/32 (31 %) 35/35 (100 %)
GCS score <8, n (%) 0 (0 %) 28/138 (20 %) 7/32 (22 %) 10/35 (29 %)
Parasitaemia (count/μl), geo
mean (95 % CI)
11,184 (6853–18,253) 27,933 (18,101–43,105) 0.007
PfHRP2 (ng/ml), geo mean
(95 % CI)a
274 (201–376) 1,684 (1,323–2,143) <0.001
Total bilirubin (mg/dl), geo
mean (95 % CI, range)
1.1 (0.9–1.4, 0.2–28.3) 2.8 (2.3–3.5, 0.2–44.2) 0.94 (0.6–1.5, 0.2–10.9) 0.47 (0.3–0.6, 0.1–6.0) <0.001
Creatinine (mg/dl), geo mean
(95 % CI, range)
1.0 (0.9–1.0, 0.5–2.3) 1.5 (1.3–1.7, 0.5–8.6) 1.7 (1.2–2.3,0.3–14.1) 1.1 (0.9–1.4, 0.6–24.3) <0.001
Acute kidney injury
(creatinine >3 mg/dl)
0/101 (0 %) 20/135 (15 %) 6/31 (19 %) 2/35 (6 %)
Hb (g/dl), mean (SD, range) 10.6 (2.8, 3.8–15.6) 9.6 (3.1, 2.6–17.5) 10.3 (3.0, 5.0–16.7) 12.3 (2.5, 4.7–16.1) <0.001
Anaemia (Hb <7 g/dl), n (%) 13 (13 %) 24 (17 %) 3 (9 %) 2 (6 %)
Glucose (mg/dl), geo mean
(95 % CI, range)
122 (114–130, 55–332) 124 (115–134, 33–455) 126 (104–152, 39–443) 146 (124–171, 63–612) 0.205
Hypoglycaemia (<40 mg/dl),
n (%)
0 (0 %) 3 (2 %) 1 (3 %) 0 (0 %)
Mortality, n (%) 0 (0 %) 39 (28 %) 16 (50 %) 15 (43 %) <0.001
Abbreviations: GCS Glasgow Coma Scale, geo mean geometric mean, Hb haemoglobin, PfHRP2 Plasmodium falciparum histidine-rich protein 2, SBP systolic blood pressure, SD standard deviation
*P values were derived by analysis of variance (ANOVA) between four participant groups (one-way ANOVA for normally distributed continuous variables or variables log-transformed toward normality; Kruskal-Wallis test
for non-normally distributed variables). Student’s t tests were used for comparison of (log-transformed) parasite count and PfHRP2 concentrations, where only two participant groups are compared. χ2 tests were used
for comparison of mortality
aOwing to limited assay availability for PfHRP2 analysis, data represent 95 participants for uncomplicated malaria and 126 for severe malaria
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Table 2 Biochemical characteristics pertaining to acidosis and calculation of strong ion gap using admission venous blood
specimens
Characteristics Uncomplicated malaria
N=102
Severe malaria
N=138
Sepsis
N=32
Encephalopathy
N=35
P value*
Na+ (mmol/L) 134 (4.73, 109–143) 136 (6.90, 108–160) 136 (11.23, 107–172) 136 (9.18, 113–157) 0.163
K+ (mmol/L) 3.6 (0.44, 2.4–5.4) 3.9 (0.81, 2.1–7.1) 4.0 (1.24, 2.0–6.9) 3.7 (0.74, 2.0–5.5) 0.003
Mg2+ (mmol/L) 0.7 (0.22, 0.1–1.1) 0.9 (0.21, 0.5–1.8) 0.8 (0.22, 0.3–1.3) 0.8 (0.13, 0.4–1.1) <0.001
Ca2+ (mmol/L) 1.9 (0.21, 1.4–2.6) 2.0 (0.21, 1.4–2.5) 1.9 (0.38, 1.1–2.6) 2.1 (0.27, 1.3–2.5) <0.001
Cl− (mmol/L) 102 (5.16, 87–113) 105 (7.87, 72–139) 106 (11.50, 78–138) 100 (9.73, 75–125) <0.001
L-Lactate (enzymatic assay)
(mmol/L), geo mean
(95 % CI, range)
1.7 (1.6–1.9, 0.8–4.6) 3.7 (3.3–4.1, 0.8–14.4) 2.9 (2.2–3.8, 0.7–15.8) 1.9 (1.4–2.5, 0.3–11.5) <0.001
Albumin (g/L) 30 (6.3, 16–46) 28 (5.8, 14–49) 28 (6.3, 18–41) 35 (6.2, 17–47) <0.001
PO4
3- (mg/dl), geo mean
(95 % CI, range)
0.7 (0.6–0.8, 0.1–3.0) 2.1 (1.8–2.3, 0.5–11.6) 3.5 (2.7–4.6, 1.0–12.9) 2.9 (2.5–3.3, 1.1–11.7) <0.001
HCO3
− (mmol/L) 23.6 (3.4, 15.4–38.9) 19.0 (5.4, 3.5–35.8) 17.0 (6.1, 4.5–30.8) 24.2 (6.5, 3.9–41.3) <0.001
pH 7.437 (0.053, 7.308–7.566) 7.398 (0.101, 6.931–7.615) 7.312 (0.182, 6.623–7.536) 7.442 (0.097, 7.054–7.549) <0.001
pCO2 (kPa) 4.8 (0.92, 3.1–8.5) 4.2 (1.04, 2.2–8.1) 4.6 (2.10, 1.8–11.1) 4.8 (1.14, 1.9–7.2) <0.001
SBD (mEq/L) +1 (+3.6, −15 to +9) +6 (+6.6, −11 to +29) +9 (+7.6, +3 to +30) 0 (+7.6, −19 to +27) <0.001
SIDeff (mEq/L) 33.5 (4.3, 22.9–50.8) 28.1 (6.1, 10.5–44.4) 26.8 (7.5, 11.4–44.2) 36.4 (6.9, 18.1–53.8) <0.001
SIDapp (mEq/L) 39.5 (4.4, 29.0–52.7) 36.3 (6.2, 13.8–52.4) 35.7 (7.2, 18.2–49.4) 43.0 (4.5, 32.1–53.3) <0.001
SIG (mEq/L) 6.0 (3.7, −5.5 to 15.1) 8.2 (4.5, −2.4 to 23.4) 8.6 (7.7, −4.9 to 30.2) 6.6 (5.1, −2.4 to 24.1) 0.002
Abbreviations: CI confidence interval, geo mean geometric mean, HCO3
− bicarbonate, pCO2 partial pressure of carbon dioxide, PO4
3- phosphate, SBD standard base
deficit; SIDapp apparent strong ion difference, SIDeff effective strong ion difference, SIG strong ion gap
For all values, means (SD, range) are reported unless stated otherwise; geometric mean, 95 % CI and range are reported for non-normally distributed variables
*P values were determined by analysis of variance between the four participant groups. Variables with a normal or near-normal distribution were analysed directly;
others were log-transformed toward normality, then analysed
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was significantly higher in severe malaria than in uncom-
plicated malaria, sepsis or encephalopathy.
There was a large difference in geometric mean (95 %
CI) plasma HPLA concentration in patients with severe
malaria (10.6 μmol/L; 9.5–11.8) compared with those
with sepsis (7.0 μmol/L; 5.4–9.0), uncomplicated mal-
aria (4.3 μmol/L; 3.7–5.0) or febrile encephalopathy
(4.4 μmol/L; 3.4–5.6). Renal function–corrected urine
concentrations of HPLA were also higher in patients
with severe malaria than in those with uncomplicated
malaria or encephalopathy.
Plasma β-HBA concentrations were significantly higher
in patients with severe malaria than in those with un-
complicated malaria. Patients with sepsis had the high-
est relative and absolute concentrations of β-HBA in
both plasma and urine. Levels of α-HBA in patients
with severe malaria, sepsis or encephalopathy were
higher than in those with uncomplicated malaria, but α-
HBA levels were not distinguishable between patients
with severe malaria and the reference groups. Corrected
α-HBA urine concentrations were higher in patients
with severe malaria than in patients with uncomplicated
malaria.Among participants with a positive SIG, the median
total proportion of SIG that could be explained by
HPLA, α-HBA and β-HBA was 3.4 % in patients with
severe malaria (interquartile range [IQR] 2.1–7.0), com-
pared with 4.2 % in patients with bacterial sepsis (IQR
2.0–15.6). The median proportion of SIG attributable to
HPLA alone was 0.13 % in severe malaria (IQR 0.09–
0.21), and 0.08 % in sepsis (IQR 0.04–0.18); these contri-
butions were significantly different (P=0.018).
Plasma creatinine was correlated with HPLA (r=0.68;
P<0.001) and β-HBA (r=0.21; P=0.016). Weaker correla-
tions were seen between bilirubin and all four acids and
between the parasite biomass marker PfHRP2 and all
four acids. GCS score correlated inversely with all four
acids. The complete correlation matrix is provided in
Additional file 1: Table S1.
Prognostic significance of organic acids and their
correlation with severity syndromes in patients with
severe malaria
Admission plasma concentrations of LA, HPLA, α-HBA
and β-HBA were each higher in patients with severe
malaria who later died than in those who survived
(Fig. 3). Of the four detectable acids, HPLA had the
Table 3 Quantification of organic acids in plasma and urine
Characteristics Uncomplicated malaria
N=102
Severe malaria
N=138
Sepsis
N=32
Encephalopathy
N=35
P value*
Geo mean (95 % CI, range) Geo mean (95 % CI, range) Geo mean (95 % CI, range) Geo mean (95 % CI, range)
Plasma concentration (μmol/La)
LA 1680 (1437–1965, 122–5019) 4912 (4389–5497, 835–27,958) 2615 (1970–3470, 305–11,002) 1898 (1380–2611, 293–17,132) <0.001
HPLA 4.3 (3.7–5.0, UD–13.0) 10.6 (9.5–11.8, 4.4–124.7) 7.0 (5.4–9.0, UD–30.0) 4.4 (3.4–5.6, UD–15.2) <0.001
α-HBA 46.0 (34.6–61.0, UD–270.1) 117.7 (106.3–130.4, 30.7–590.1) 88.4 (59.4–131.5, UD–411.3) 86.8 (63.8–118.1, 6.4–419.7) <0.001
β-HBA 102.7 (91.9–114.8, UD–715.7) 143.9 (128.9–160.5, UD–1620.0) 223.5 (147.4–338.8, UD–2720.0) 146.8 103.9–207.3, UD–1651.0) <0.001
Corrected urine concentrations
(μmol/mmol CrCl)a,b
N=78 N=112 N=19 N=26
LA 2.85 (2.32–3.49, 0.44–41.77) 12.97 (9.67–17.40, 0.54–1357.22) 13.47 (5.54–32.74, 1.00–555.30) 10.92 (6.05–19.72, 1.45–215.30) <0.001
HPLA 0.48 (0.34–0.66, 0.01–7.08) 1.61 (1.28–2.04, 0.05–19.61) 1.15 (0.46–2.85, 0.03–17.12) 0.50 (0.29–0.88, UD–5.82) <0.001
α-HBA 0.63 (0.51–0.78, 0.08–11.86) 1.26 (0.98–1.63, UD–79.63) 1.06 (0.61–1.84, 0.19–17.37) 1.16 (0.91–1.48, 0.36–4.57) <0.001
β-HBA 2.11 (1.75–2.53, UD–11.99) 3.42 (2.83–4.12, UD–193.30) 5.52 (2.66–11.46, UD–36.28) 3.40 (2.27–5.09, UD–17.11) <0.001
EMA 0.34 (0.27–0.43, 0.06–17.46) 0.26 (0.21–0.32, UD–9.58) 0.37 (0.0.24–0.57, UD–2.33) 0.36 (0.26–0.49, UD–2.25) 0.145
MMA 0.23 (0.19–0.28, 0.03–2.85) 0.20 (0.16–0.24, UD–2.97) 0.19 (0.13–0.27, UD–0.45) 0.21 (0.14–0.31, 0.05–4.75) 0.646
α-KGA 2.25 (1.72–2.95, UD–5.44) 3.18 (2.53–3.98, UD–27.11) 3.52 (1.82–6.82, UD–12.91) 3.89 (2.58–5.86, UD–26.41) 0.128
Abbreviations: LA lactic acid, geo mean geometric mean, HPLA hydroxyphenyllactic acid, α-HBA α-hydroxybutyric acid, β-HBA β-hydroxybutyric acid, EMA ethylmalonic acid, MMA methylmalonic acid, α-KGA α-ketoglutaric acid,
CrCl creatinine clearance, UD undetectable
*Acid concentrations were log-transformed toward normality before analysis of variance. For plasma specimens, undetectable concentrations were treated as half the lower limit of detection to allow inclusion in
intergroup comparisons. For corrected urine concentrations, undetectable values were treated as half the lowest value calculated from a detectable specimen
aFor all plasma specimens, EMA, MMA, α-KGA and malonic acid (MA) were assayed but undetectable. For all urine specimens, MA was assayed but undetectable
bCorrected urine concentrations were adjusted for impaired creatinine clearance by incorporating the urine/plasma creatinine ratio as described in the Methods section
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Fig. 1 Plasma strong ion gap (SIG), standard base deficit (SBD) and concentrations of lactic acid (LA), hydroxyphenyllactic acid (HPLA), α-hydroxybutyric
acid (α-HBA) and β-hydroxybutyric acid (β-HBA). Black bars above the scatterplots denote significantly different participant groups identified with
Tukey’s test and P<0.05. Error bars represent medians and interquartile ranges
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(95 % CI 0.70–0.87), followed by LA with an AUROCC
of 0.77 (95 % CI 0.69–0.86). The AUROCC for SBD
was 0.75 (95 % CI 0.65-0.85), and the AUROCC for
pH was 0.74 (95 % CI 0.64–0.83). Urine LA and HPLA
also had prognostic value, but less than that of their
plasma concentrations (data not shown).
Logistic regression models were developed for pa-
tients with severe malaria, with in-hospital death as
the dependent variable, to assess the prognostic
value of plasma and urine organic acid concentra-
tions (Table 4). An alternative multivariate model
using clinical variables, including creatinine and
PfHRP2, was undertaken, but it did not improve the
performance of the model (data not shown). In the
model of plasma acids in 138 patients (39 of whom
died), HPLA and LA had independent prognostic
value, with the combined model providing an AUR-
OCC of 0.81. Among 112 participants with available
urine specimens (34 of whom died), LA was the only
urinary acid of significant independent prognosticvalue. The AUROCC for a model based on urinary
LA alone was 0.72.
Discussion
Metabolic acidosis with an increased SIG and high
SBD is a prominent feature of severe falciparum
malaria, and severity of the acidosis is closely linked
to mortality [4, 16, 23]. The present study shows
that organic acids other than lactate also have a
strong prognostic significance for death in adult pa-
tients with severe malaria. HPLA, α-HBA and β-
HBA were all present at higher concentrations in
plasma and urine of patients with severe malaria
than in those with uncomplicated disease and also
at higher plasma concentrations in patients who
died than in those who survived. This identifies
HPLA as an acid with strong independent prognostic
significance, despite low absolute concentration. The
elevation of HPLA was more pronounced in severe
malaria than in patients with severe sepsis, whereas SBD
and SIG were elevated in both groups. Patients
Fig. 2 Urine concentrations of organic acids corrected for renal function. Black bars above the scatterplots denote significantly different participant
groups identified with Tukey’s test and P<0.05. Error bars represent medians and interquartile ranges. Abbreviations: CrCl creatinine clearance, LA lactic
acid, HPLA hydroxyphenyllactic acid, α-HBA α-hydroxybutyric acid, β-HBA β-hydroxybutyric acid
Herdman et al. Critical Care  (2015) 19:317 Page 8 of 11with febrile encephalopathy were not acidotic, but some
showed a strongly elevated SIG, suggesting a potential
pathophysiological role for organic acids; however, the
profile of acids we describe in severe malaria is distinct
from that of non-malarial encephalopathy [24].
LA was detectable in plasma at a considerably higher
concentrations than any other organic acid and was a
strong independent predictor of death in patients with se-
vere malaria, with a higher AUROCC than reported previ-
ously [4]. We consistently observed higher concentrations
of LA detected by LC-MS than we did with the con-
ventional enzymatic assay. This may reflect the fact that
conventional enzymatic assays detect only the L-lactate
isomers, whereas LC-MS detects both L- and D-isomers.
Human metabolic pathways produce only L-lactate, but
both isomers are produced by P. falciparum, as the para-
site relies heavily on incomplete oxidation of glucose into
LA for its own energy supplies [25]. Bacterially derived D-
lactate can accumulate in the context of multiorganfailure, with increased transposition of bacteria from the
ischaemic gastrointestinal tract [26–28], and it is note-
worthy that D-lactate can cause an encephalopathy in
humans ranging from disorientation to coma [29]. The
hypothesis that D-lactate could contribute to the patho-
genesis of severe malaria requires further quantification
and study.
HPLA was identified at higher concentrations in the
plasma and urine of participants with severe malaria
than in reference groups, and it was a strong and inde-
pendent predictor of mortality in patients with severe
malaria. Although total HPLA concentrations were rela-
tively low, the high prognostic value of HPLA may
reflect perturbations in associated metabolic pathways,
with related acids also contributing to the total acid load.
Alternatively, this may indicate strong biological activity
of the anion at low concentrations or local accumulation
in affected tissues. HPLA is a product of L-tyrosine ca-
tabolism [30]. Plasma and urine HPLA concentrations
Fig. 3 Plasma concentrations of organic acids in severe malaria,
stratified by disease outcome. Comparisons are drawn between
patients who survived to discharge (n=99) and those who died
(n=39). For all four acids, plasma concentrations were significantly
higher among patients who later died, by unpaired t test of
log-transformed concentrations (P<0.001 for LA, HPLA and β-HBA;
P=0.001 for α-HBA). Error bars represent medians and interquartile
ranges. Abbreviations: LA lactic acid, HPLA hydroxyphenyllactic acid,
α-HBA α-hydroxybutyric acid, β-HBA β-hydroxybutyric acid
Table 4 Summary of logistic regression models based on plasma ac
for probability of fatal outcome in participants with severe malaria
Univariate analysis
β (95 % CI) OR (95 % CI)
Regression of plasma acid concentrations
LA 1.74 (1.00–2.47) 5.67 (2.72–11.86)
HPLA 1.76 (1.02–2.51) 5.82 (2.76–12.26)
α-HBA 1.22 (0.53–1.91) 3.40 (1.71–6.78)
β-HBA 1.09 (0.45–1.73) 2.98 (1.57–5.64)
Regression of urine acid concentrations
LA 0.54 (0.25–0.84) 1.723 (1.28–2.31)
HPLA 0.58 (0.21–0.96) 1.791 (1.23–2.61)
α-HBA 0.23 (−0.06 to +0.52) 1.259 (0.94–1.68)
β-HBA 0.38 (0.02–0.74) 1.459 (1.02–2.09)
MMA −0.03 (−0.36 to +0.29) 0.966 (0.70– 1.34)
EMA 0.12 (−0.22 to +0.46) 1.126 (0.80–1.58)
α-KGA −0.13 (−0.43 to +0.16) 0.877 (0.65–1.18)
Abbreviations: OR odds ratio, LA lactic acid, HPLA hydroxyphenyllactic acid, α-HBA α-
methylmalonic acid, α-KGA α-ketoglutaric acid, AUROCC area under the receiver ope
Goodness of fit of the plasma acid model: AUROCC=0.81; Hosmer-Lemeshow=0.94;
Hosmer-Lemeshow=0.72; P=0.459, N=112. Concentrations were log-transformed to
included in the model, then backward stepwise selection was performed, removing
Herdman et al. Critical Care  (2015) 19:317 Page 9 of 11are very low in health, but higher levels have been
described in the context of critical illness [18, 31–35].
Adults with post-operative sepsis or hepatic encephalopathy
have increased plasma and urine concentrations [34, 36].
Urinary excretion of HPLA has also been described in
patients with tyrosinaemia type III, a rare inborn error of
metabolism [37]. In these patients with neurological impair-
ment, 4-hydroxyphenylpyruvate dioxygenase, the enzyme
that converts hydroxyphenylpyruvate (HPPA) to homogen-
tisate, is deficient, causing diversion of HPPA to HPLA.
This raises the possibility that increased HPLA levels in se-
vere malaria could be related to a functional blockade in
the downstream pathway of HPPA. Interestingly, phenylala-
nine—an indirect precursor of HPPA—is elevated in both
paediatric and adult patients with severe malaria [38, 39].
In addition to human metabolic pathways, gastrointestinal
microflora (including Enterococcus faecalis, Escherichia coli,
bifidobacteria and lactobacilli) can be a source of HPLA
[35]. High levels of parasite sequestration occur in the
gastrointestinal vasculature in severe malaria [40]. This
could drive local ischaemia and bacterial translocation, with
higher levels of HPLA entering the circulation. HPLA
accumulation may also reflect changes to routes of clear-
ance in severe disease. Its strongest identified biochemical
correlation is with creatinine, so it may accumulate
disproportionately in patients with kidney injury. It is
noteworthy that other phenolic acids have been
shown to influence brain metabolism in experimental
studies in vivo and in vitro, altering neuronal andid concentrations (N=138) or urine acid concentrations (N=112)
Multivariate analysis
P β (95 % CI) OR (95 % CI) P
<0.001 1.24 (0.43–2.05) 3.45 (1.54–7.76) 0.003
<0.001 1.25 (0.48–2.02) 3.48 (1.61–7.52) 0.001
0.001 – –
0.001 – –
<0.001 0.54 (0.25– 0.84) 1.72 (1.28–2.31) <0.001
0.002 – –
0.118 – –
0.039 – –
0.836 – –
0.489 – –
0.382 – –
hydroxybutyric acid, β-HBA β-hydroxybutyric acid, EMA ethylmalonic acid, MMA
rating characteristic curve
P=0.612, N=138. Goodness of fit of the urine acid model: AUROCC=0.72;
normality before analysis. All variables in univariate analysis were initially
variables on the basis of P≥0.05
Herdman et al. Critical Care  (2015) 19:317 Page 10 of 11glial metabolism and inducing coma in rats [41–43]. A po-
tential neurobiological role of HPLA in severe and cere-
bral malaria remains to be further elucidated.
β-HBA was high in plasma and urine of patients with
severe malaria but highest in patients with severe sep-
sis. Concentrations were not independently correlated
with mortality. β-HBA is synthesised in the liver from
free fatty acids, and increased production of ketoacids
can be related to the augmented metabolic demand,
coupled with reduced oral caloric intake, in severe ill-
ness [18, 44, 45]. Elevated plasma β-HBA has been as-
sociated with severe malaria and other severe illnesses
among children in Kenya [44].
Concentrations of α-HBA were high in patients with
severe malaria, sepsis or encephalopathy, but they were
not an independent predictor of mortality. α-HBA is a
product of threonine and methionine catabolism, but it
is also produced in glutathione synthesis during the con-
version of cystathionine to cysteine. The glutathione
pathway is upregulated to counteract oxidative stress,
which is increased during severe malaria [22, 46]. Raised
α-HBA levels may thus reflect increased production of
glutathione. Raised levels of α-HBA have been found in
the urine of patients with lactic acidosis, which may be
related to the redox state of the cell [47].
We acknowledge the limitations of this hypothesis-
generating study and the need for further, targeted ex-
ploration of the mechanisms by which the identified
acids influence the pathogenesis of malaria. The hetero-
geneity of organ dysfunction in both severe malaria and
severe sepsis complicates our understanding of both
conditions, particularly with regard to the metabolic
pathways implicated. This heterogeneity reduces the
statistical power of our analysis; yet, significant conclu-
sions emerge.
Conclusions
Concentrations of HPLA were significantly higher in
patients with severe malaria than in patients with sep-
sis, febrile encephalopathy or uncomplicated malaria,
which suggests a disease-specific role. HPLA also has
prognostic significance independent of LA. Further
research into the kinetics and biological effects of these
acids, as well as into the contributing metabolic path-
ways, is warranted.
Key messages
 Previously unmeasured organic acids could be
identified in patients with severe falciparum malaria
using a novel targeted LC-MS approach.
 A tyrosine metabolite and two ketoacids were
detected at increased concentrations in patients with
severe malaria. Lactate and 4-hydroxyphenyllactic acid were
predictive of mortality in patients with severe malaria.
 Our findings highlight metabolic pathways
potentially implicated in disease pathogenesis.
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